Onyx Biotec (NSE:ONYX) EBIT: ₹7.9 Mil (TTM As of Mar. 2026)


NSE:ONYX Onyx Biotec Ltd NSE:ONYX
13 GF Score
Price ₹38.95
! 6 Warning Signs
View Full Analysis

What is Onyx Biotec EBIT?

Onyx Biotec NSE:ONYX 13 EBIT is ₹7.9 Mil as of Mar. 2026. GuruFocus rates NSE:ONYX with a GF Score™ of 13/100. The stock has 6 warning signs investors should review.

Onyx Biotec's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹11.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹7.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Onyx Biotec's annualized ROC % for the quarter that ended in Mar. 2026 was 2.67%. Onyx Biotec's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Onyx Biotec's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.97%.

Onyx Biotec  (NSE:ONYX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Onyx Biotec's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=19.21 * ( 1 - 0% )/( (706.357 + 734.709)/ 2 )
=19.21/720.533
=2.67 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=921.242 - 142.999 - ( 71.886 - max(0, 289.42 - 512.474+71.886))
=706.357

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=951.546 - 176.463 - ( 40.374 - max(0, 325.27 - 512.783+40.374))
=734.709

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Onyx Biotec's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=23.34/( ( (398.351 + max(237.291, 0)) + (428.352 + max(244.219, 0)) )/ 2 )
=23.34/( ( 635.642 + 672.571 )/ 2 )
=23.34/654.1065
=3.57 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(268.043 + 120.458 + 34.389) - (142.999 + 0 + 42.6)
=237.291

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(274.981 + 140.396 + 49.293) - (176.463 + 0 + 43.988)
=244.219

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Onyx Biotec's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=7.898/817.588
=0.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onyx Biotec EBIT Related Terms

Onyx Biotec EBIT Historical Data

* Premium members only.

The historical data trend for Onyx Biotec's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onyx Biotec EBIT Chart

Onyx Biotec Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
43.10 31.12 65.97 84.64 7.90

Onyx Biotec Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial 0.00 51.66 32.98 -3.77 11.67

NSE:ONYX vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Onyx Biotec's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Onyx Biotec EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Onyx Biotec's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Onyx Biotec's EV-to-EBIT falls into.


NSE:ONYX
13GF Score
Onyx Biotec Ltd NSE:ONYX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onyx Biotec EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹7.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹7.9 Mil mean?
Onyx Biotec (NSE:ONYX) has a EBIT of ₹7.9 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Onyx Biotec.
Is Onyx Biotec's EBIT too high?
Onyx Biotec's current EBIT is ₹7.9 Mil. Overall, Onyx Biotec has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's EBIT compare to ISRG and BDX?
Onyx Biotec's EBIT of ₹7.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Onyx Biotec. Onyx Biotec's current EBIT is ₹7.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current EBIT of ₹7.9 Mil. The current EBIT is ₹7.9 Mil. Onyx Biotec's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current EBIT is ₹7.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onyx Biotec Business Description

Address Nalagarh Road, Near Sainimajraropar, Village Bir Plassi, Solan, HP, IND, 174101
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
13GF Score

Get the complete analysis for NSE:ONYX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹38.95
Price